Trial Profile
Randomized Comparison of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent With a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients Treated With Percutaneous Coronary Intervention
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary) ; Sirolimus
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms SORT OUT IX
- 17 Sep 2020 Planned End Date changed from 1 Oct 2021 to 1 Oct 2023.
- 12 May 2020 Results published in the Circulation.
- 14 Mar 2019 Trial design published in the American Heart Journal